Mitrofanova, A.
Mallela, S. K.
Ducasa, G. M.
Yoo, T. H.
Rosenfeld-Gur, E.
Zelnik, I. D.
Molina, J.
Varona Santos, J.
Ge, M.
Sloan, A.
Kim, J. J.
Pedigo, C.
Bryn, J.
Volosenco, I. http://orcid.org/0000-0003-0580-1811
Faul, C.
Zeidan, Y. H.
Garcia Hernandez, C.
Mendez, A. J.
Leibiger, I.
Burke, G. W.
Futerman, A. H.
Barisoni, L.
Ishimoto, Y. http://orcid.org/0000-0001-5773-8637
Inagi, R. http://orcid.org/0000-0001-7032-7736
Merscher, S.
Fornoni, A.
Funding for this research was provided by:
- NIH/NIDDK USA is National Institute of Health/ National Institute of Diabetes and Digestive and Kidney Diseases, USA
Article History
Received: 20 June 2018
Accepted: 15 May 2019
First Online: 19 June 2019
Competing interests
: G.W.B., A.F., and S.M. are inventors on pending or issued patents (US10,183,038, US10,052,345) aimed to diagnose or treat proteinuric renal diseases. They stand to gain royalties from their future commercialization. A.F. is Chief Scientific Officer of L&F Health LLC and is consultant for Variant Pharmaceutical. Variant Pharmaceuticals, Inc. has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin for treatment of kidney disease from L&F Research. S.M. holds equity interest in a company presently commercializing the form of cyclodextrin referenced in this paper. The patent associated with the use of hydroxypropyl-beta-cyclodextrin is published under US10,195,227. A.F. is Chief Medical Officer of LipoNexT, LLC. The remaining authors delare no competing interests.